Answer
Efficacy of intravenous isatuximab has not been established in children with relapsed or refractory acute lymphoblastic or myeloid leukaemia, although it has been studied outside its authorised indications in children aged 28 days to less than 18 years.
Sources for this answer
- SARCLISA 20mg/mL concentrate for solution for infusionSANOFI · emc · SmPC §4.2 Posology and method of administration · Version 10Document updated
Sources checked